Literature DB >> 25510261

Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan.

Y T Chen1,2, Y J Chen2,3, C Y Hwang1,2,4, M W Lin5, T J Chen6, C C Chen1,2, S Y Chu1,2, D D Lee1,2, Y T Chang1,2, H N Liu1,2,7.   

Abstract

BACKGROUND: The previous literature has demonstrated the association of autoimmune and atopic diseases with vitiligo, but there has been no large-scale nationwide study conducted to confirm this.
OBJECTIVES: The present study was conducted to clarify the comorbid profiles in vitiligo patients and thereby better understand their clinical scenarios and underlying pathogenesis.
METHODS: This was a retrospective population-based study conducted from 1996 to 2011 via the National Health Insurance Research Database in Taiwan. The differences in the prevalence of multiple autoimmune and atopic diseases between case subjects and controls were analysed by multiple logistic regression method.
RESULTS: A total of 14883 vitiligo patients and 59532 controls were enroled. The prevalence of vitiligo was 0.064% and the peak of onset age was 40-59 years old. The non-stratified analysis evidenced a significant association between vitiligo and several comorbid diseases, including alopecia areata, Hashimoto thyroiditis, myasthenia gravis, psoriasis, Graves' disease, Sjögren's syndrome, systemic lupus erythematosus and atopic dermatitis. Vitiligo patients also had higher prevalence of multiple comorbidities than controls. In the age- and gender-stratified analysis, increased risks of systemic lupus erythematosus and Sjögren's syndrome were observed only in subjects aged 60-79. The association of vitiligo with myasthenia gravis and rheumatoid arthritis was identified only in the subgroup aged 20-39 and in females aged 60-79 respectively.
CONCLUSION: Our study not only confirmed the significant association of vitiligo with multiple autoimmune and atopic diseases in Taiwan but also disclosed several unique findings, including the much lower prevalence of vitiligo, delayed onset of vitiligo by three decades, different associated comorbidity profiles comparing to westerners and the age- and gender-specific approach for the vitiligo-associated comorbidities.
© 2014 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2014        PMID: 25510261     DOI: 10.1111/jdv.12870

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  16 in total

1.  Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo.

Authors:  R Dey-Rao; A A Sinha
Journal:  Genes Immun       Date:  2015-11-12       Impact factor: 2.676

2.  [Vitiligo: Clinical presentation and pathogenesis].

Authors:  M Schild; M Meurer
Journal:  Hautarzt       Date:  2016-02       Impact factor: 0.751

3.  Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression.

Authors:  Ying Jin; Genevieve H L Roberts; Tracey M Ferrara; Songtao Ben; Nanja van Geel; Albert Wolkerstorfer; Khaled Ezzedine; Janet Siebert; Charles P Neff; Brent E Palmer; Stephanie A Santorico; Richard A Spritz
Journal:  Nat Commun       Date:  2019-01-23       Impact factor: 14.919

4.  Association between vitiligo and smoking: A nationwide population-based study in Korea.

Authors:  Ji Hyun Lee; Yong Gyu Park; Young Bok Lee; Soo Young Lee; Dong Soo Yu; Kyung Do Han
Journal:  Sci Rep       Date:  2020-04-10       Impact factor: 4.379

Review 5.  Novel immunological and genetic factors associated with vitiligo: A review.

Authors:  Salvador Luis Said-Fernandez; Celia Nohemi Sanchez-Domínguez; Mauricio Andres Salinas-Santander; Herminia Guadalupe Martinez-Rodriguez; David Emmanuel Kubelis-Lopez; Natalia Aranza Zapata-Salazar; Osvaldo Tomas Vazquez-Martinez; Uwe Wollina; Torello Lotti; Jorge Ocampo-Candiani
Journal:  Exp Ther Med       Date:  2021-02-01       Impact factor: 2.447

6.  A Nationwide, Multicentric Case-Control Study on Vitiligo (MEDEC-V) to Elicit the Magnitude and Correlates.

Authors:  Nilendu Sarma; Sayantani Chakraborty; Shital Poojary; B M Shashi Kumar; Lalit Kumar Gupta; Leelavathy Budamakuntla; Leishiwon Kumrah; Suchibrata Das; Ajay Govindrao Ovhal; Nirmal Kumar Mandal; Shuvankar Mukherjee; T V Anoop; Binod Kumar Thakur; L Eswari; Joan Felicita Samson; Krina Bharat Patel; Rajesh Rajagopalan; Sanjeev Gupta; Tejinder Kaur
Journal:  Indian J Dermatol       Date:  2020 Nov-Dec       Impact factor: 1.494

7.  Epidemiology of Vitiligo - A Dual Population-Based Approach.

Authors:  Nicole Mohr; Jana Petersen; Natalia Kirsten; Matthias Augustin
Journal:  Clin Epidemiol       Date:  2021-05-26       Impact factor: 4.790

8.  The Prevalence of Vitiligo: A Meta-Analysis.

Authors:  Yuhui Zhang; Yunfei Cai; Meihui Shi; Shibin Jiang; Shaoshan Cui; Yan Wu; Xing-Hua Gao; Hong-Duo Chen
Journal:  PLoS One       Date:  2016-09-27       Impact factor: 3.240

9.  Systematic review of atopic dermatitis disease definition in studies using routinely collected health data.

Authors:  M P Dizon; A M Yu; R K Singh; J Wan; M-M Chren; C Flohr; J I Silverberg; D J Margolis; S M Langan; K Abuabara
Journal:  Br J Dermatol       Date:  2018-04-25       Impact factor: 9.302

10.  Uremic pruritus and long-term morbidities in the dialysis population.

Authors:  Sze-Wen Ting; Pei-Chun Fan; Yu-Sheng Lin; Ming-Shyan Lin; Cheng-Chia Lee; George Kuo; Chih-Hsiang Chang
Journal:  PLoS One       Date:  2020-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.